Immunotherapy using pullulan‐conjugated Der f 2 allergen in canine atopic dermatitis: An anti‐inflammatory agent‐sparing approach
Veterinary Dermatology · 2025
DOI: 10.1111/vde.13315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, 2025. Verfasst von Masahiko Nagata und 7 weiteren Autor:innen. Beteiligte Einrichtung: ASC, Chofu, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Glucans, Antigens, Dermatophagoides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nippon Zenyaku Kogyo.
Abstract (Originalsprache)
Background
Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD).
Objective
To assess the anti‐inflammatory agent‐sparing effect over 1 year of immunotherapy using pullulan‐conjugated recombinant Der f 2 (rDf2‐P). Animals Twenty‐one privately owned dogs with cAD. Materials and Methods Dogs with mild clinical signs after ≥4 weeks of anti‐inflammatory drug treatment received rDf2‐P immunotherapy for 1 year. A monthly medication score (MS) was calculated, and clinical signs were assessed using Canine Atopic Dermatitis Extent and Severity Index (CADESI)‐04, cAD Eczema Area and Severity for Shiba Inu and pruritus scores. Serum thymus and activation‐regulated chemokine (TARC)/C‐C Motif Chemokine Ligand‐17 (CCL17) concentrations were assessed at the initial and final doses during the 6‐week induction phase and every 3 months for 1 year thereafter in 16 cases.
Results
The mean MS decreased significantly by 43.0% ( p = 0.022), 60.9% ( p = 0.003), 70.0% ( p = 0.0004), 58.7% ( p = 0.0004) and 49.3% ( p = 0.029) at 2.5, 4.5, 7.5, 10.5 and 13.5 months, respectively. Drug‐sparing effects, assessed with MS and adjusted by clinical scores were rated as excellent for 12 (57.1%) and 11 (52.4%) dogs, good for 3 (14.3%) and 1 (4.8%) dogs, fair for 0 and 3 (14.3%) dogs, and poor for 6 (28.6%) and 5 (23.8%) dogs at 4.5 and 13.5 months, respectively. The serum TARC/CCL17 concentrations were significantly lower in the samples with lower CADESI‐04 scores (17) ( p = 0.0002). Conclusions and Clinical Relevance Der f 2‐P immunotherapy can lead to a rapid reduction in anti‐inflammatory drug use and serve as an effective proactive therapy for cAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ASC, Chofu, Tokyo, Japan.
- Ai Animal Hospital Kashima, Fukushima, Japan.
- Yoshida Animal Hospital, Tamana, Kumamoto, Japan.
- Hanawa Animal Hospital, Yoichi, Hokkaido, Japan.
- Cookie Animal Hospital, Sakai, Osaka, Japan.
- Miyaki Animal Clinic, Miyaki, Saga, Japan.
Förderung
- Nippon Zenyaku Kogyo
Zitieren
APA
Nagata, M., Kozakai, J., Yoshida, A., Kameyama, K., Oboso, H., Muto, H., Ogino, S., & Tsukui, T. (2025). Immunotherapy using pullulan‐conjugated Der f 2 allergen in canine atopic dermatitis: An anti‐inflammatory agent‐sparing approach. Veterinary Dermatology. https://doi.org/10.1111/vde.13315
Vancouver
Nagata M, Kozakai J, Yoshida A, Kameyama K, Oboso H, Muto H, et al. Immunotherapy using pullulan‐conjugated Der f 2 allergen in canine atopic dermatitis: An anti‐inflammatory agent‐sparing approach. Veterinary Dermatology. 2025. doi:10.1111/vde.13315
BibTeX
@article{Nagata2025,
author = {Nagata, Masahiko and Kozakai, Jin and Yoshida, Aya and Kameyama, Kana and Oboso, Hiromi and Muto, Hisanori and Ogino, Shoji and Tsukui, Toshihiro},
title = {Immunotherapy using pullulan‐conjugated Der f 2 allergen in canine atopic dermatitis: An anti‐inflammatory agent‐sparing approach},
journal = {Veterinary Dermatology},
year = {2025},
doi = {10.1111/vde.13315}
}
EUVIMED